8 Nov 2023 • Tirzepatide treatment significantly reduces the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes. Tirzepatide has previously shown significant glycated haemoglobin (HbA1c) and weight reduction in the SURPASS clinical trial programme in adults with T2D, without any indication of an increase in the risk of major cardiovascular events.

SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m2 and at least one weight-related complication, excluding diabetes. Participants were randomly assigned to tirzepatide (5/10/15 mg) or placebo.

Overall, treatment with tirzepatide significantly reduced the 10-year predicted risk of ASCVD compared with placebo in people with obesity or overweight but without diabetes. The absolute reduction in risk was greater for participants with higher ASCVD risk at baseline.

Source: Diabetes, Obesity & Metabolism | Read full story